Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
Therapy Name | Anti-BCMA CAR-T cells + Cyclophosphamide + Fludarabine |
Synonyms | |
Therapy Description |
Anti-BCMA CAR T Cells are T-cells that express a chimeric antigen receptor targeting B-cell maturation antigen (BCMA), which may induce an enhanced anti-tumor immune response against BCMA-expressing tumor cells (PMID: 23344265). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Anti-BCMA CAR-T cells | CART-BCMA|CT053 | Anti-BCMA CAR-T cells are T-cells engineered to express a chimeric antigen receptor (CAR) targeting BCMA, which may enhance antitumor immune response (PMID: 23344265). | ||
Cyclophosphamide | Cytoxan | CPM | Chemotherapy - Alkylating 18 | Cytoxan (cyclophosphamide) is an alkylating agent, which inhibits DNA replication (NCI Drug Dictionary). Cytoxan (cyclophosphamide) is FDA approved in multiple hematological malignancies, breast cancer, neuroblastoma, ovarian cancer, and retinoblastoma (NCI Drug Dictionary). |
Fludarabine | Fludara | FAMP|Fludarabine phosphate | Flurdara (fludarabine) is converted to 2-fluoro-ara-ATP intracellularly, which potentially inhibits DNA polymerase alpha, ribonucleotide reductase and DNA primase, leading to decreased DNA synthesis and reduced tumor growth (NCI Drug Dictionary) |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT03602612 | Phase I | Anti-BCMA CAR-T cells + Cyclophosphamide + Fludarabine | T Cells Expressing a Novel Fully-Human Anti-BCMA CAR for Treating Multiple Myeloma | Active, not recruiting | USA | 0 |
NCT05577000 | Phase I | Anti-BCMA CAR-T cells + Cyclophosphamide + Fludarabine | Anti-BCMA Chimeric Antigen Receptor T Cells for Relapsed or Refractory Multiple Myeloma | Active, not recruiting | USA | 0 |